Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLET study in first-line hepatocellular carcinoma
2022-501217-31-00Phase 3Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Atezolizumab + bevacizumab with Ipilimumab + atezolizumab + bevacizumab (2 arms). Primary endpoints: Objective response within first 24 weeks and Overall survival. Started Mar 2023; status: completed.
02
Drugs
ipilimumabatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-501217-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501217-31-00.